Michael Guger

1.1k total citations
38 papers, 425 citations indexed

About

Michael Guger is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Michael Guger has authored 38 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 15 papers in Neurology and 7 papers in Oncology. Recurrent topics in Michael Guger's work include Multiple Sclerosis Research Studies (26 papers), Peripheral Neuropathies and Disorders (8 papers) and Polyomavirus and related diseases (7 papers). Michael Guger is often cited by papers focused on Multiple Sclerosis Research Studies (26 papers), Peripheral Neuropathies and Disorders (8 papers) and Polyomavirus and related diseases (7 papers). Michael Guger collaborates with scholars based in Austria, Germany and United States. Michael Guger's co-authors include Fritz Leutmezer, Thomas Berger, Christian Enzinger, Franziska Di Pauli, Jörg Kraus, Erich Kvas, Harald Hegen, Gerhard Ransmayr, Gudrun Zulehner and Paulus Rommer and has published in prestigious journals such as The Lancet, PLoS ONE and Neurology.

In The Last Decade

Michael Guger

34 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Guger Austria 12 207 160 103 94 57 38 425
Saúl Reyes Colombia 10 300 1.4× 147 0.9× 167 1.6× 59 0.6× 31 0.5× 38 496
Pablo A. López Argentina 12 286 1.4× 171 1.1× 80 0.8× 39 0.4× 26 0.5× 53 449
Stéphane Debeugny France 8 200 1.0× 176 1.1× 32 0.3× 39 0.4× 148 2.6× 18 537
Antonio Ianniello Italy 10 205 1.0× 113 0.7× 55 0.5× 32 0.3× 19 0.3× 28 334
Margareta A. Clarke United Kingdom 12 374 1.8× 196 1.2× 116 1.1× 61 0.6× 29 0.5× 31 626
Ansu Noronha United States 10 112 0.5× 46 0.3× 40 0.4× 34 0.4× 84 1.5× 20 390
Ernie Willoughby New Zealand 9 244 1.2× 62 0.4× 17 0.2× 49 0.5× 39 0.7× 11 386
Enric Monreal Spain 9 115 0.6× 271 1.7× 135 1.3× 29 0.3× 27 0.5× 33 479
Nada Abou-Fayssal United States 5 122 0.6× 119 0.7× 89 0.9× 55 0.6× 13 0.2× 7 247
Elizabeth Crabtree United States 7 235 1.1× 97 0.6× 19 0.2× 34 0.4× 20 0.4× 9 389

Countries citing papers authored by Michael Guger

Since Specialization
Citations

This map shows the geographic impact of Michael Guger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Guger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Guger more than expected).

Fields of papers citing papers by Michael Guger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Guger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Guger. The network helps show where Michael Guger may publish in the future.

Co-authorship network of co-authors of Michael Guger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Guger. A scholar is included among the top collaborators of Michael Guger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Guger. Michael Guger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ponleitner, Markus, Nik Krajnc, Tobias Zrzavy, et al.. (2025). Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). Journal of Neurology. 272(12). 774–774.
2.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2024). Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria. Journal of Neurology. 271(6). 3142–3152. 2 indexed citations
3.
4.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2023). Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria. Journal of Neurology. 270(6). 3103–3111. 2 indexed citations
5.
Bsteh, Gabriel, Nik Krajnc, Franziska Di Pauli, et al.. (2022). Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study. European Journal of Neurology. 29(10). 3050–3060. 20 indexed citations
6.
Bsteh, Gabriel, Harald Hegen, Nik Krajnc, et al.. (2022). Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. European Journal of Neurology. 29(5). 1538–1544. 15 indexed citations
7.
Bsteh, Gabriel, Harald Hegen, Franziska Di Pauli, et al.. (2022). Impact of vaccination on COVID‐19 outcome in multiple sclerosis. European Journal of Neurology. 29(11). 3329–3336. 12 indexed citations
8.
Schwingenschuh, Petra, Franz A. Fellner, Michael Guger, et al.. (2022). Differences in aphasia syndromes between progressive supranuclear palsy–Richardson’s syndrome, behavioral variant frontotemporal dementia and Alzheimer’s dementia. Journal of Neural Transmission. 129(8). 1039–1048. 2 indexed citations
9.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2021). Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. Journal of Neurology. 268(11). 4303–4310. 12 indexed citations
10.
Bsteh, Gabriel, Harald Hegen, Fritz Leutmezer, et al.. (2021). Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. Multiple Sclerosis Journal. 27(14). 2209–2218. 22 indexed citations
11.
Amprosi, Matthias, Michael Zech, Ruth Steiger, et al.. (2020). Familial writer’s cramp: a clinical clue for inherited coenzyme Q10 deficiency. Neurogenetics. 22(1). 81–86. 5 indexed citations
12.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2020). Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry. Frontiers in Neurology. 11. 676–676. 5 indexed citations
13.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2019). Real‐life use of oral disease‐modifying treatments in Austria. Acta Neurologica Scandinavica. 140(1). 32–39. 9 indexed citations
14.
Topakian, Raffi, Fritz Zimprich, Stephan Iglseder, et al.. (2019). High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. Journal of Neurology. 266(3). 699–706. 61 indexed citations
15.
Houtchens, Maria K., Ángela Vidal‐Jordana, Michael Guger, et al.. (2018). Disease activity during pregnancy after Fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis (P5.032). Neurology. 90(15_supplement). 3 indexed citations
16.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2017). Real‐life clinical use of natalizumab and fingolimod in Austria. Acta Neurologica Scandinavica. 137(2). 181–187. 22 indexed citations
17.
18.
Hegen, Harald, Michael Guger, Andrea Harrer, et al.. (2013). High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) – A pilot study. Multiple Sclerosis and Related Disorders. 3(2). 220–226. 2 indexed citations
19.
Struhal, Walter, et al.. (2012). Attempted suicide under high dose dopaminergic therapy including apomorphine. Wiener klinische Wochenschrift. 124(13-14). 461–463. 9 indexed citations
20.
Höpfl, R., Michael Guger, & Andreas Widschwendter. (2001). Humane Papillomviren und ihre Rolle bei der Karzinogenese. Der Hautarzt. 52(9). 834–848. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saúl Reyes Breakdown of academic impact, for papers by Pablo A. López Breakdown of academic impact, for papers by Stéphane Debeugny Breakdown of academic impact, for papers by Antonio Ianniello Breakdown of academic impact, for papers by Margareta A. Clarke Breakdown of academic impact, for papers by Ansu Noronha Breakdown of academic impact, for papers by Ernie Willoughby Breakdown of academic impact, for papers by Enric Monreal Breakdown of academic impact, for papers by Nada Abou-Fayssal Breakdown of academic impact, for papers by Elizabeth Crabtree
Rankless by CCL
2026